molnupiravir

11/30/2023 - "Molnupiravir treatment in at-risk, unvaccinated patients resulted in improved clinical outcomes for most participant-reported COVID-19 symptoms compared with placebo. "
11/23/2023 - "The randomized, placebo-controlled, double-blind MOVe-OUT trial demonstrated molnupiravir (800 mg every 12 h for 5 days) as safe and effective for outpatient treatment of mild-to-moderate COVID-19, significantly reducing the risk of hospitalization/death in high-risk adults. "
08/01/2023 - "Evidence from clinical studies showed that Molnupiravir caused significant reduction in the risk of hospitalization or death in high-risk mild COVID-19 patients. "
01/01/2023 - "This study suggests that in the era of Omicron and in real-life setting, molnupiravir might be effective in reducing the risk of severe COVID-19 and COVID-19-related mortality, particularly in specific subgroups."
10/26/2021 - "Molnupiravir (MK-4482, EIDD-2801) is an experimental drug that has been demonstrated to be effective for the treatment of COVID-19 in human clinical trials. "

01/01/2023 - "In conclusion, our results indicated that molnupiravir has the potential to be an effective treatment for PEDV infection."
01/01/2021 - "Molnupiravir proved to be effective against infections with each of the variants and therefore may have potential combating current and future emerging VoCs."
08/01/2023 - "In vitro and in vivo efficacy of Molnupiravir against Zika virus infections."
01/01/2023 - "Treating SARS-CoV-2 Omicron variant infection by molnupiravir for pandemic mitigation and living with the virus: a mathematical modeling study."
12/01/2021 - "This study aims to evaluate the potential of repurposing molnupiravir for treating seasonal human coronavirus (HCoV) infections. "

02/15/2023 - "The current meta-analysis included six studies that indicated that the risk of mortality was reduced by 34%, and the risk of composite outcome of disease progression was reduced by 37% among patients who received molnupiravir. "
01/01/2023 - "At a median follow-up of 102 days (IQR, 56-225 days), molnupiravir use was associated with a lower risk of all-cause mortality and/or hospitalization (HR, 0.71 [95% CI, 0.64-0.79]; P < .001) and in-hospital disease progression (HR, 0.49 [95% CI, 0.35-0.69]; P < .001) compared with nonuse. "
10/08/2022 - "Molnupiravir use was associated with lower risks of death (HR 0·76 [95% CI 0·61-0·95]) and in-hospital disease progression (0·57 [0·43-0·76]) than non-use was, whereas risk of hospitalisation was similar in both groups (0·98 [0·89-1·06]). "
11/01/2022 - "In this study, we evaluate the efficacy and safety of molnupiravir in Indian patients with mild SARS-CoV-2 infection and at least one risk factor for disease progression (CTRI/2021/05/033739). "
05/01/2022 - "Based on the cumulative evidence from preclinical and clinical studies, Molnupiravir is proven to be a well tolerated, direct acting oral anti-viral agent to halt the disease progression in mild to moderate COVID-19 cases; in terms of mortality and hospitalization rates."

01/01/2023 - "Further studies revealed that molnupiravir can reverse changes in the transcriptome caused by viral infection. "
12/20/2022 - "Our results predicted and explained the failure of molnupiravir in hospitalized patients and highlighted the utility of preclinical pharmacodynamic studies to design optimal antiviral regimens for the treatment of viral diseases. "
01/01/2023 - "In this context, molnupiravir (prodrug of EIDD-1931) is the most efficacious orally against corona virus disease (COVID-19). "
01/01/2023 - "We propose oxidative DNA damage via CDA-mediated metabolism as a possible mutagenic mechanism of NHC, highlighting the need for careful risk assessment of molnupiravir use in therapies for viral diseases, including COVID-19."
07/01/2022 - "Favipiravir, molnupiravir, and ritonavir have been recently approved as the first oral antivirals for treatment of SARS-CoV-2 viral infections. "

02/01/2022 - "At the beginning of this pandemic, molnupiravir was in preclinical development for seasonal influenza. "
10/01/2021 - "When the pandemic began, molnupiravir was in pre-clinical development for the treatment of seasonal influenza. "
09/24/2021 - "Molnupiravir was originally developed for the treatment of influenza at Emory University, USA. "
01/01/2020 - "These results provide an experimental basis in a human disease-relevant influenza animal model for clinical testing of EIDD-2801."
01/01/2020 - "Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model."